Erythromycin → HCID 66602471, 화합물

HRID 443787

반응식

HRID 443787 반응식
C(OCC)(=O)CCCCC.[Zn:11].[CH3:12][CH2:13][C@H:14]1[O:29][C:27](=[O:28])[C@H:26]([CH3:30])[C@@H:25]([O:31][C@@H:32]2[O:37][C@@H:36]([CH3:38])[C@H:35]([OH:39])[C@@:34]([O:41][CH3:42])([CH3:40])[CH2:33]2)[C@H:24]([CH3:43])[C@@H:23]([O:44][C@@H:45]2[O:50][C@H:49]([CH3:51])[CH2:48][C@H:47]([N:52]([CH3:54])[CH3:53])[C@H:46]2[OH:55])[C@@:22]([OH:57])([CH3:56])[CH2:21][C@@H:20]([CH3:58])[C:18](=[O:19])[C@H:17]([CH3:59])[C@@H:16]([OH:60])[C@@:15]1([OH:62])[CH3:61]>C(OC(C)C)(=O)CCCCCCCCC(OC(C)C)=O>[Zn:11].[CH3:12][CH2:13][C@H:14]1[O:29][C:27](=[O:28])[C@H:26]([CH3:30])[C@@H:25]([O:31][C@@H:32]2[O:37][C@@H:36]([CH3:38])[C@H:35]([OH:39])[C@@:34]([O:41][CH3:42])([CH3:40])[CH2:33]2)[C@H:24]([CH3:43])[C@@H:23]([O:44][C@@H:45]2[O:50][C@H:49]([CH3:51])[CH2:48][C@H:47]([N:52]([CH3:53])[CH3:54])[C@H:46]2[OH:55])[C@@:22]([OH:57])([CH3:56])[CH2:21][C@@H:20]([CH3:58])[C:18](=[O:19])[C@H:17]([CH3:59])[C@@H:16]([OH:60])[C@@:15]1([OH:62])[CH3:61]

참가 물질

4

반응물 2

HCID 12560ErythromycinHCID 87133346ZINC 2-ethyl hexanoate

생성물 1

HCID 66602471HCID 66602471, 화합물

시약·촉매·용매 1

HCID 24096Diisopropyl Sebacate용매

실험 절차

In a similar procedure, zinc 2-ethyl hexanoate (slight excess) is combined with erythromycin base, at room temperature in diisopropyl sebacate, to provide a zinc erythromycin compound, presumably as the complex zinc di-erythromycin di-2-ethylhexanoate.

출처 및 근거

ORD 기록
ord-d3272f2f7d034668a4ad024a64a5e0d6
출처 데이터셋
uspto-grants-1981_04
특허 번호
US04261982

연결된 노트

불러오는 중…